Pembrolizumab Plus ICE: ‘Acceptable’ Salvage for Relapsed/Refractory Hodgkin Lymphoma
Pembrolizumab plus ICE chemotherapy was deemed “tolerable and efficacious.”
Pembrolizumab plus ICE chemotherapy was deemed “tolerable and efficacious.”
Researchers sought to determine whether tumor microenvironment levels of M2 macrophages could predict response to nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Researchers sought to determine whether interleukin-6 levels would be predictive of survival in patients with Hodgkin lymphoma receiving nivolumab.
Researchers sought to determine whether patients with relapsed or refractory classical Hodgkin lymphoma can receive benefit when retreated with nivolumab.
The excess risk of cardiovascular disease from involved-field radiotherapy was 6.2%.
Researchers sought to determine whether patients with lymphoma would develop antibodies with a COVID-19 vaccine 6 months after treatment with anti-CD20-containing therapy.
Researchers sought to determine the fertility-related issues and approaches for survivors of Hodgkin lymphoma and diffuse large B-cell lymphoma.
The overall response rate was 100%.
The median overall survival was not reached at 3 years.
A deepened understanding of long-term effects can help clinicians to better determine upfront therapy and monitoring strategies for pediatric patients with Hodgkin lymphoma.